Identification of a site for a cohort study on natural history of HIV infection in Ethiopia

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 17, Issue 2, 1998, Pages 149-155

  Sahlu, T ^a,b   Fontanet, A ^a   Rinke De Wit, T ^a   Messele, T ^a   Doorly, R ^a   Yeneneh, H ^b   Bindels, P ^c   Coutinho, R ^c  

^a Ethiopian Netherlands AIDS Res P   (Ethiopia)

^b ETHIOPIAN PUBLIC HEALTH INSTITUTE   (Ethiopia)

^c MUNICIPAL HEALTH SERVICE   (Netherlands)

Author keywords

Cohort site; Ethiopia; Natural history of HIV infection

Indexed keywords

ADULT; ARTICLE; COMORBIDITY; DISEASE COURSE; ETHIOPIA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MIGRATION; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; SEXUAL BEHAVIOR; SOCIOECONOMICS; SYPHILIS;

EID: 0032007085     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199802010-00008     Document Type: Article

References (37)

1. Feinberg MB. Changing the natural history of HIV disease. Lancet 1996;348:239-46.
2. Hessol NA, Koblin BA, van Griesven GJP, et al. Progression of Human Immunodeficiency Virus type 1 (HIV-1) infection among homosexual men in hepatitis B vaccine trial cohorts in Amsterdam, New York City, and San Francisco, 1978-1991. Am J Epidemiol 1994;139:1077-87
3. Diamondstone LS, Blakley SA, Rice JC, et al. Prognostic factors for all-cause mortality among hemophiliacs infected with Human Immunodeficiency Virus. Am J Epidemiol 1995;142:304-13.
4. Mientjes GH, van Ameijden EJ, van den Hoek AJAR, Coutinho RA. Increasing morbidity without rise in non-AIDS mortality among HIV-infected intravenous drug users in Amsterdam. AIDS 1992;6:207-12.
5. Selwyn PA, Alcabes P, Hartel D, et al. Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. N Engl J Med 1992;327:1697-703.
6. Tersmette M, Schuitemaker H. Virulent HIV strains. AIDS 1993; 7:1123-5.
7. Peeters M, Piot P, van der Groen G. Variability among HIV and SIV strains of African origin. AIDS 1991;5(Suppl 1):S29-36.
8. Morrow RH, Colebunders RL, Chin J. Interaction of HIV infection with epidemic tropical diseases. AIDS 1989;3(Suppl):S79-87.
9. Klein MR, Keet IPM, D'Amaro J, et al. Associations between HLA frequencies and pathogenic features of human immunodeficiency virus type 1 infection in seroconverters from the Amsterdam cohort of homosexual men. J Infect Dis 1994;169:1244-9.
10. Baum MK, Shor-Posner G, Lu Y, et al. Micronutrient and HIV-1 disease progression. AIDS 1995;9:1051-6.
11. Bentwich Z, Kalinkovich A and Weisman Z. Immune activation is a dominant factor in the pathogenesis of African AIDS. Immunol Today 1995;16:187-91.
12. Moroz C, Weisman Z, Kalinkovich A, et al. Increased p43-isoferritin in Ethiopian immigrants in Israel - a marker for immune activation. AIDS 1994;8:135-6.
13. Whittle H, Egboga A, Todd J, et al. Clinical and laboratory predictors of survival in Gambian patients with symptomatic HIV-1 or HIV-2 infection. AIDS 1992;6:685-9.
14. Sirivichayakul S, Phanuphak P, Hanvanich M, et al. Clinical correlation of the immunological markers of HIV infection in individuals from Thailand. AIDS 1992;6:393-7.
15. Chollet-Martin S, Simon F, Matheron S, et al. Comparison of plasma cytokine levels in African patients with HIV-1 and HIV-2 infection. AIDS 1994;8:879-84.
16. Marlink R, Kanki P, Thior I, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994; 265:1587-90.
17. Morgan D, Malamba SS , Maude GH, et al. HIV-1 natural history cohort and survival times in rural Uganda. AIDS 1997;11:633-40.
18. Leroy V, Msellati P, Lepage P, et al. Four years of natural history of HIV-1 infection in African women: a prospective cohort study in Kigali (Rwanda), 1988-1993. J Acquir Immune Defic Syndr Hum Retrovirol 1995;9:415-21.
19. Laga M, Alary M, Nzila N, et al. Condom promotion, sexually transmitted diseases treatment, and declining incidence of HIV-1 infection in female Zairian sex workers. Lancet 1994;344:246-8.
20. Anzala OA, Nagelkerke NJD, Bwayo JJ, et al. Rapid progression to disease in African sex workers with human immunodeficiency virus type 1 infection. J Infect Dis 1995;171:686-9.
21. Heyward WL, Osmanov S, Saba J, et al. Preparation for phase III HIV vaccine efficacy trials: methods for the determination of HIV incidence. AIDS 1994;8:1285-91.
22. Buve A, Carael M, Hayes R, et al. Variations in HIV prevalence between urban areas in sub-Saharan Africa: do we understand them? AIDS 1995;9(Suppl A):S103-9.
23. Kane F, Alary M, Ndoye I, et al. Temporary expatriation is related to HIV-1 infection in rural Senegal. AIDS 1993;7:1261-5.
24. Nunn AJ, Wagner HU, Kamali A, et al. Migration and HIV-1 seroprevalence in a rural Ugandan population. AIDS 1995;9:503-6.
25. Ayehune S, Johansson B, Sonnerborg A, et al. Sequence analysis of selected regions of the env (V3 loop and gp41) and gag (p7) reading frames of Ethiopian human immunodeficiency virus type 1 strains. Arch Virol 1993;128:229-39.
26. Abebe A, Kuiken C, Goudsmit J, et al. HIV-1 subtype C in Addis Ababa, Ethiopia. AIDS Res Human Retroviruses 1997;13:1071-5.
27. Dixon DO, Rida WN, Fast PE, et al. HIV vaccine trials: some design issues including sample size calculation. J Acquir Immune Defic Syndr Hum Retrovirol 1993;6:485-96.
28. Weniger BG. Experience from HIV incidence cohorts in Thailand: implications for HIV vaccine efficacy trials. AIDS 1994;8:1007-10.
29. Smith PG, Hayes RJ, Mulder DW. Epidemiological and public health considerations in the design of HIV vaccine trials. AIDS 1991;5(Suppl 2):S105-11.
30. Haynes BF. HIV vaccines: where we are and where we are going. Lancet 1996;348:933-7.
31. Lurie P, Bishaw M, Chesney MA, et al. Ethical, behavioral, and social aspects of hiv vaccine trials in developing countries. JAMA 1994;271:295-301.
32. Chesney MA, Lurie P, Coates TJ. Strategies for addressing the social and behavioral challenges of prophylactic HIV vaccine trials. J Acquir Immune Defic Syndr Human Retrovirol 1995;9: 30-5.
33. Ministry of Health. National AIDS program review report. Addis Ababa, Ethiopia: Ministry of Health, 1994.
34. Laga M, Nzila N, Goeman J. The interrelationship of sexually transmitted diseases and HIV infection: implications for the control of both epidemics in Africa. AIDS 1991;5(Suppl 1):S55-63.
35. Cameron DW, Simonsen JN, D'Costa L, et al. Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconverssion in men. Lancet 1989;2:403-7.
36. Laga M, Manoka A, Kivuvu M, et al. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS 1993;7:95-102.
37. Bulterys M, Chao A, Habimana P, et al. Incident HIV-1 infection in a cohort of young women in Butare, Rwanda. AIDS 1994;8: 1585-91.